311 related articles for article (PubMed ID: 23335703)
21. Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol.
Riccio E; Zanfardino M; Franzese M; Capuano I; Buonanno P; Ferreri L; Amicone M; Pisani A
Mol Genet Genomic Med; 2021 May; 9(5):e1659. PubMed ID: 33755336
[TBL] [Abstract][Full Text] [Related]
22. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
23. Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study.
Mignani R; Americo C; Aucella F; Battaglia Y; Cianci V; Sapuppo A; Lanzillo C; Pennacchiotti F; Tartaglia L; Marchi G; Pieruzzi F
Orphanet J Rare Dis; 2024 Feb; 19(1):38. PubMed ID: 38308295
[TBL] [Abstract][Full Text] [Related]
24. A revised home treatment algorithm for Fabry disease: influence of antibody formation.
Smid BE; Hoogendijk SL; Wijburg FA; Hollak CE; Linthorst GE
Mol Genet Metab; 2013 Feb; 108(2):132-7. PubMed ID: 23332169
[TBL] [Abstract][Full Text] [Related]
25. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
Khan A; Sirrs SM; Bichet DG; Morel CF; Tocoian A; Lan L; West ML;
Drugs R D; 2021 Dec; 21(4):385-397. PubMed ID: 34542871
[TBL] [Abstract][Full Text] [Related]
26. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
Deegan PB
J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
[TBL] [Abstract][Full Text] [Related]
27. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
28. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
29. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.
Krämer J; Lenders M; Canaan-Kühl S; Nordbeck P; Üçeyler N; Blaschke D; Duning T; Reiermann S; Stypmann J; Brand SM; Gottschling T; Störk S; Wanner C; Sommer C; Brand E; Weidemann F
Nephrol Dial Transplant; 2018 Aug; 33(8):1362-1372. PubMed ID: 29186537
[TBL] [Abstract][Full Text] [Related]
30. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
Tsuboi K; Yamamoto H
Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22498845
[TBL] [Abstract][Full Text] [Related]
31. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.
Kampmann C; Perrin A; Beck M
Orphanet J Rare Dis; 2015 Sep; 10():125. PubMed ID: 26416388
[TBL] [Abstract][Full Text] [Related]
33. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
[TBL] [Abstract][Full Text] [Related]
34. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
Tsuboi K; Yamamoto H
Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22878505
[TBL] [Abstract][Full Text] [Related]
35. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data.
Feriozzi S; Chimenti C; Reisin RC
Drug Des Devel Ther; 2024; 18():1083-1101. PubMed ID: 38585254
[TBL] [Abstract][Full Text] [Related]
36. Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands.
Linthorst GE; Vedder AC; Ormel EE; Aerts JM; Hollak CE
Nephrol Dial Transplant; 2006 Feb; 21(2):355-60. PubMed ID: 16249196
[TBL] [Abstract][Full Text] [Related]
37. [Home-based infusion therapy--a feasible approach for chronically ill patients? A new path to provide superior patient care exemplified for Fabry's disease].
Beck M; Gaedeke J; Martus P; Karabul N; Rolfs A
Dtsch Med Wochenschr; 2013 Nov; 138(46):2345-50. PubMed ID: 24193859
[TBL] [Abstract][Full Text] [Related]
38. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
[TBL] [Abstract][Full Text] [Related]
39. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
40. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.
Weidemann F; Krämer J; Duning T; Lenders M; Canaan-Kühl S; Krebs A; Guerrero González H; Sommer C; Üçeyler N; Niemann M; Störk S; Schelleckes M; Reiermann S; Stypmann J; Brand SM; Wanner C; Brand E
J Am Soc Nephrol; 2014 Apr; 25(4):837-49. PubMed ID: 24556354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
